• Latest Posts

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas meets primary endpoint in gastric cancer study

Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming

Treatment for hot flushes and night sweats accepted for regulatory review by EMA

Astellas, Seagen and Merck give details on urothelial cancer treatment

Astellas ‘encouraged’ by menopause symptom treatment results in China


Astellas to create new biotech campus in South San Francisco

Mogrify and Astellas to address sensorineural hearing loss

Anti-Aging Treatments at Forefront of Astellas’ €80M UK Acquisition

Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas

Massive €800M Acquisition of Belgian Biotech treating Menopause

The Largest Deals, Fundraising and Exits of 2016 in European Biotech